Phase 2b clinical trials in ulcerative colitis
The Phase 2b study is conducted to evaluate the efficacy and the safety of obefazimod, taken orally once daily by patients with moderate-to-severe ulcerative colitis. The induction study has been completed and the corresponding open-label maintenance trial is ongoing. No more patients can be included into this study.
Only patients who conclude the “induction phase” of a study have the possibility to roll over into the “maintenance phase”, where long-term effects of the treatment are evaluated.